Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Jabil Inc (JBL) vs Eli Lilly And Co (LLY) Price & Performance

Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Jabil Inc vs Eli Lilly And Co — how do they compare? Jabil Inc trades at $359.89 (market cap $35.27B), while Eli Lilly And Co trades at $1,215 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 31.2× Jabil Inc's market cap, and Eli Lilly And Co pays the higher dividend (0.56%). Which is the better fit depends on your goals.

JBLLLY
Market Cap
$35.27B$1.10T
Sector
TechnologyHealth
52-Week High
$385.50$1.24K
52-Week Low
$192.49$639.43
Enterprise Value
$37.81B$1.14T
Dividend Yield
0.1%0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Jabil Inc

Jabil trades at $341.22, down 1.0% today but maintains strong momentum with a bullish technical outlook and consistent earnings beats. The stock shows robust fundamentals with revenue growth from $29.8B in 2025 to $33.6B projected for 2026, supported by AI infrastructure demand and diversified operations. Recent news highlights Jabil's 31.6% six-month surge and strategic expansion with a new logistics hub in Penang.

Jabil presents a compelling growth story driven by AI and manufacturing excellence, with analyst consensus pointing to significant upside (target $448.29). However, elevated valuation multiples (P/E 42.13) and competitive pressures in the EMS sector warrant caution. The stock's technical strength and fundamental momentum support a positive outlook, though investors should monitor execution risks and market volatility.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.

Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Jabil Inc

Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.

Read more on JBL

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY